2.20
+0.065(+3.05%)
Currency In USD
| Previous Close | 0.93 |
| Open | 1.9 |
| Day High | 2.18 |
| Day Low | 1.65 |
| 52-Week High | 2.81 |
| 52-Week Low | 0.4 |
| Volume | 112.1M |
| Average Volume | 2.06M |
| Market Cap | 171.72M |
| PE | 5.61 |
| EPS | 0.38 |
| Moving Average 50 Days | 0.65 |
| Moving Average 200 Days | 0.97 |
| Change | 1.2 |
If you invested $1000 in CytomX Therapeutics, Inc. (CTMX) since IPO date, it would be worth $165.12 as of May 13, 2025 at a share price of $2.13. Whereas If you bought $1000 worth of CytomX Therapeutics, Inc. (CTMX) shares 5 years ago, it would be worth $147.51 as of May 13, 2025 at a share price of $2.13.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
CytomX Therapeutics Announces Pricing of $100 Million Underwritten Offering of Common Stock
GlobeNewswire Inc.
Yesterday at 10:50 AM GMT
SOUTH SAN FRANCISCO, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (NASDAQ:CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced the pricing of an underwritten offering of 76,923
CytomX Announces Positive Interim Data From Phase 1 Dose Escalation Study of EpCAM Antibody Drug Conjugate (CX-2051) Candidate in Patients with Advanced Colorectal Cancer (CRC)
GlobeNewswire Inc.
Yesterday at 10:15 AM GMT
- 28% confirmed response rate (5/18) per RECIST v1.1 in unselected patients across doses prioritized for expansion (7.2, 8.6 and 10 mg/kg Q3W) - - 3 of 7 evaluable patients (43%) with confirmed responses at upper expansion dose (10 mg/kg Q3W) - - Med
CytomX Therapeutics to Report First Quarter 2025 Financial Results on May 12, 2025
GlobeNewswire Inc.
May 05, 2025 12:00 PM GMT
SOUTH SAN FRANCISCO, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report first quarter financial results on Monda